Publication:
Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients

dc.contributor.authorSahin, Fahri
dc.contributor.authorSaydam, Guray
dc.contributor.authorComert, Melda
dc.contributor.authorUz, Burak
dc.contributor.authorYavuz, Akif Selim
dc.contributor.authorTuran, Esra
dc.contributor.authorEskazan, Ahmet Emre
dc.contributor.authorIDSahin, Handan Haydaroglu/0000-0002-3467-8819
dc.contributor.authorIDAr, Muhlis Cem/0000-0002-0332-9253
dc.contributor.authorIDSaydam, Guray/0000-0001-8646-1673
dc.contributor.authorIDSoysal, Teoman/0000-0002-7417-2118
dc.contributor.authorIDPaydas, Semra/0000-0003-4642-3693
dc.contributor.authorIDDemirkan, Fatih/0000-0002-1172-8668
dc.contributor.authorIDSahin, Fahri/0000-0001-9315-8891
dc.contributor.authorIDKirkizlar, Hakki Onur/0000-0001-7523-8599
dc.contributor.authorIDEskazan, Ahmet Emre/0000-0001-9568-0894
dc.contributor.authorIDGURKAN, EMEL/0000-0002-3060-4054
dc.contributor.authorIDHaznedaroglu, Ibrahim C./0000-0001-8028-9462
dc.contributor.authorIDTuzuner, Nukhet/0000-0002-8686-7822
dc.date.accessioned2020-06-21T14:04:16Z
dc.date.available2020-06-21T14:04:16Z
dc.date.issued2013
dc.departmentOMÜen_US
dc.department-temp[Sahin, Fahri -- Saydam, Guray -- Comert, Melda] Ege Univ, Fac Med, Dept Hematol, Izmir, Turkey -- [Uz, Burak -- Haznedaroglu, Ibrahim C.] Hacettepe Univ, Fac Med, Dept Hematol, TR-06100 Ankara, Turkey -- [Yavuz, Akif Selim -- Turan, Esraen_US
dc.description.abstractObjective: here have been tremendous changes in treatment and follow-up of patients with chronic myeloid leukemia (CML) in the last decade. Especially, regular publication and updating of NCCN and ELN guidelines have provided enermous rationale and base for close monitorization of patients with CML. But, it is stil needed to have registry results retrospectively to evaluate daily CML practices. Materials and Methods: In this article, we have evaluated 1133 patients' results with CML in terms of demographical features, disease status, response, resistance and use of second-generation TKIs. Results: The response rate has been found relatively high in comparison with previously published articles, and we detected that there was a lack of appropriate and adequate molecular response assessment. Conclusion: We concluded that we need to improve registry systems and increase the availability of molecular response assessment to provide high-quality patient care.en_US
dc.identifier.doi10.4274/tjh.2013.0151
dc.identifier.endpage358en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue4en_US
dc.identifier.pmid24385824
dc.identifier.startpage351en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.2013.0151
dc.identifier.urihttps://hdl.handle.net/20.500.12712/15588
dc.identifier.volume30en_US
dc.identifier.wosWOS:000331341700002
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.journalTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Myeloid Leukemiaen_US
dc.subjectRegistryen_US
dc.subjectResponseen_US
dc.titleTurkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patientsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files